The Readout Loud
239: 2022 in review, CEO indictments, & the year ahead
This episode isn’t summarized yet
Create a free account and summarize it. In a few minutes you’ll have the key takeaways and a section-by-section summary.
Show notes
We look back on the biggest biotech stories of 2022 and how, despite some meaningful advances in Alzheimer's disease and gene therapy, the industry seems stuck in a sentiment rut. We also discuss the latest news in the life sciences, including a pair of indicted CEOs and the debate over how much an oft-debated new medicine should cost.